Scientific Advisory Board
Dr. Lauster is a professor at the Technische Universität Berlin and head of the university’s Department of Medical Biotechnology. He is also a faculty member in the Berlin-Brandenburg Center for Regenerative Therapies. Dr. Lauster does research on the molecular biology of rheumatic disease as well as on stem cells, development and signaling in the mammalian hair follicle. He received his habilitation in the genetics department at the Free University of Berlin.
Previously, he was a group leader at the German Arthritis Research Center (DRFZ) in Berlin. Prior to that, he was a member of the Basel Institute for Immunology. He received his Ph.D. degree at the Max Planck Institute for Molecular Genetics in Berlin. He studied biology at the University of Bielefeld and at the Free University of Berlin.
Dr. Spielmann recently retired as Director of ZEBET of the German Federal Institute for Risk Assessment (German acronym BfR) in Berlin, where he also served as a professor. Since then, he has served as a consultant to the President of the BfR and an honorary professor for regulatory toxicology on the faculty of the Free University of Berlin (FUB).
In addition he was appointed State Animal Welfare Comissioner of the State of Berlin. Prior to joining the FUB in 2007, he established and served as head of the National German Center for the Documentation and Evaluation of Alternatives to Animal Experiments (German acronym ZEBET). Prior to that, he was director and professor regulating the safety of chemicals at the German Federal Health Institute (German acronym BGA) in Berlin.
Dr. Spielmann trained as a medical doctor and received his degree at FUB with specializations in pharmacology, toxicology and clinical pharmacology.
Dr. Christine Günther has been active since 2008 as Chief Executive Officer, Chief Manufacturing Officer and Qualified Person at apceth GmbH & Co. KG, one of the leading companies in the development, manufacturing and clinical implementation of Advanced Therapy Medicinal Products (ATMPs) in Europe.
She is a specialist in clinical hematology and oncology with extensive experience in clinical stem cell transplantation, transplantation immunology and cell therapies. Her particular area of expertise is pharmaceutical development of complex cell-based and gene therapy products.
Prior to joining apceth, Dr. Günther worked as qualified person, head of quality control and medical director at the public German stem cell and cord blood bank, focusing on stem cell and tissue procurement, donor testing, characterization of cell products and their application to the patient including cord blood products for malignant diseases. Prior to that, she gained extensive experience as hematologist / oncologist during her years at the University Hospital in Munich (Germany).
Dr. Walles is a professor at the University Hospital Wuerzburg and is holding the Chair Tissue Engineering and Regenerative Medicine (TERM), University Hospital Wuerzburg. In addition, she’s head of the Translational Center Wuerzburg <Regenerative therapies in oncology and musculoskelettal diseases>, a division of Fraunhofer IGB.
The scientific foci of Heike Walles and her Team are: (I) Technologies for tissue engineering (TE), (II) 3D tissue models and (III) the development of cell-based implants for regenerative medicine (RegMed). From 2004 to 2009 she was Head of the Department Cell Systems of the Fraunhofer-Institute IGB in Stuttgart. She held a Junior Professor ship <Tissue Engineering> at the Medical School Hannover (MHH), was the coordinator of the Interdisciplinary Network Tissue Engineering at the MHH and Head of R&D at ARTISS GmbH, Hannover.
She received her Ph.D. degree at the Max Planck Institute for Biochemistry and the Ludwig-Maximillian-University Munich and studied biology at the University of Giessen.
Prof. Dr. Hans-Dieter Volk has been director of the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) since its establishment in 2006. In addition, he is head of the Institute of Medical Immunology at the Charité - Universitätsmedizin Berlin since 1994, and the Department of Immunology of the Labor Berlin-Charité Vivantes GmbH since 2011. Taking a translational approach, Prof. Volk combines basic and clinical research in immunology. This has allowed him and his team to develop new diagnostic products and therapies for immune diseases, which are already on the market.
His research work focuses on the development of biomarkers, transplantation immunology, the immunopathogenesis of virus infections of the herpes group of viruses, and the role of inhibitory cytokines and regulatory T cells. Hans-Dieter Volk works closely with other research groups at Charité – Universitätsmedizin Berlin and the BCRT as well as a number of biotech and pharma companies and the Charité Research Organization GmbH to translate his research findings into clinical applications as quickly as possible. The institute has spawned a number of successful biotech spin-off companies including Jerini AG, ProBioGen AG, T Cell Europe GmbH and Cellserve GmbH.